FBRX Relative Valuation
FBRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FBRX is overvalued; if below, it's undervalued.
Historical Valuation
Forte Biosciences Inc (FBRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.79. The fair price of Forte Biosciences Inc (FBRX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：26.30
Fair
-7.26
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Forte Biosciences Inc. (FBRX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.41. The thresholds are as follows: Strongly Undervalued below -10.89, Undervalued between -10.89 and -6.15, Fairly Valued between 3.33 and -6.15, Overvalued between 3.33 and 8.08, and Strongly Overvalued above 8.08. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-5.93
EV/EBIT
Forte Biosciences Inc. (FBRX) has a current EV/EBIT of -5.93. The 5-year average EV/EBIT is -2.41. The thresholds are as follows: Strongly Undervalued below -14.71, Undervalued between -14.71 and -8.56, Fairly Valued between 3.75 and -8.56, Overvalued between 3.75 and 9.90, and Strongly Overvalued above 9.90. The current Forward EV/EBIT of -5.93 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Forte Biosciences Inc. (FBRX) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Forte Biosciences Inc. (FBRX) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.22. The thresholds are as follows: Strongly Undervalued below -10.15, Undervalued between -10.15 and -5.69, Fairly Valued between 3.24 and -5.69, Overvalued between 3.24 and 7.71, and Strongly Overvalued above 7.71. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-8.93
P/FCF
Forte Biosciences Inc. (FBRX) has a current P/FCF of -8.93. The 5-year average P/FCF is -4.23. The thresholds are as follows: Strongly Undervalued below -17.65, Undervalued between -17.65 and -10.94, Fairly Valued between 2.47 and -10.94, Overvalued between 2.47 and 9.18, and Strongly Overvalued above 9.18. The current Forward P/FCF of -8.93 falls within the Historic Trend Line -Fairly Valued range.
Forte Biosciences Inc (FBRX) has a current Price-to-Book (P/B) ratio of 5.01. Compared to its 3-year average P/B ratio of 1.24 , the current P/B ratio is approximately 303.18% higher. Relative to its 5-year average P/B ratio of 1.99, the current P/B ratio is about 151.81% higher. Forte Biosciences Inc (FBRX) has a Forward Free Cash Flow (FCF) yield of approximately -10.59%. Compared to its 3-year average FCF yield of -99.03%, the current FCF yield is approximately -89.31% lower. Relative to its 5-year average FCF yield of -75.19% , the current FCF yield is about -85.92% lower.
5.01
P/B
Median3y
1.24
Median5y
1.99
-10.59
FCF Yield
Median3y
-99.03
Median5y
-75.19
Competitors Valuation Multiple
The average P/S ratio for FBRX's competitors is 4863.59, providing a benchmark for relative valuation. Forte Biosciences Inc Corp (FBRX) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of FBRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of FBRX in the past 1 year is driven by Unknown.
People Also Watch
ABOS
Acumen Pharmaceuticals Inc
1.83USD
-8.04%
SDST
Stardust Power Inc
3.67USD
-1.61%
SUNS
Sunrise Realty Trust Inc
9.4USD
-0.95%
NUKK
Nukkleus Inc
4.1699USD
22.65%
MGX
Metagenomi Inc
1.785USD
-0.83%
RECT
Rectitude Holdings Ltd
1.69USD
-1.74%
CRDL
Cardiol Therapeutics Inc
1.01USD
0.00%
MDXH
MDxHealth SA
3.33USD
-0.30%
FRD
Friedman Industries Inc
19.47USD
0.31%
Frequently Asked Questions
Is Forte Biosciences Inc (FBRX) currently overvalued or undervalued?
Forte Biosciences Inc (FBRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.79. The fair price of Forte Biosciences Inc (FBRX) is between to according to relative valuation methord.
What is Forte Biosciences Inc (FBRX) fair value?
FBRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Forte Biosciences Inc (FBRX) is between to according to relative valuation methord.
How does FBRX's valuation metrics compare to the industry average?
The average P/S ratio for FBRX's competitors is 4863.59, providing a benchmark for relative valuation. Forte Biosciences Inc Corp (FBRX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Forte Biosciences Inc (FBRX) as of Jan 08 2026?
As of Jan 08 2026, Forte Biosciences Inc (FBRX) has a P/B ratio of 5.01. This indicates that the market values FBRX at 5.01 times its book value.
What is the current FCF Yield for Forte Biosciences Inc (FBRX) as of Jan 08 2026?
As of Jan 08 2026, Forte Biosciences Inc (FBRX) has a FCF Yield of -10.59%. This means that for every dollar of Forte Biosciences Inc’s market capitalization, the company generates -10.59 cents in free cash flow.
What is the current Forward P/E ratio for Forte Biosciences Inc (FBRX) as of Jan 08 2026?
As of Jan 08 2026, Forte Biosciences Inc (FBRX) has a Forward P/E ratio of -7.26. This means the market is willing to pay $-7.26 for every dollar of Forte Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Forte Biosciences Inc (FBRX) as of Jan 08 2026?
As of Jan 08 2026, Forte Biosciences Inc (FBRX) has a Forward P/S ratio of 0.00. This means the market is valuing FBRX at $0.00 for every dollar of expected revenue over the next 12 months.